Etrasimod
An S1P receptor modulator, approved in ulcerative colitis and trialled in alopecia areata.
No public activity in over 18 months
- Developed by
- Pfizer
- Current phase
- Phase 2
- Indications
- Alopecia areata
- Also known as
- APD334, Velsipity
- Last public activity
- June 2024
- Record confidence
- Medium
Tests whether it works, at what dose, in a few hundred people.
Why it matters
S1P modulators work by keeping lymphocytes in the lymph nodes rather than letting them circulate into tissue — an entirely different way of stopping an attack on the follicle from either blocking a cytokine signal or depleting a cell type. Another already-approved molecule being redirected, which shortens the safety runway if it works.
Development history
- Phase 2
First Phase 2 trial on record: NCT04556734 — Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
ClinicalTrials.gov ↗
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata
Pfizer · n=80 · July 2020
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Etrasimod (APD334) in alopecia areata — ClinicalTrials.gov